DOCSLIB.ORG

Involvement of Spinal Protein Kinase Cγ in the Attenuation of Opioid Μ

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Involvement of Spinal Protein Kinase Cγ in the Attenuation of Opioid Μ The Journal of Neuroscience, June 1, 2001, 21(11):3715–3720 Involvement of Spinal Protein Kinase C␥ in the Attenuation of Opioid ␮-Receptor-Mediated G-Protein Activation after Chronic 2 4 5 Intrathecal Administration of [D-Ala ,N-MePhe ,Gly-Ol ]Enkephalin Minoru Narita,1,2 Hirokazu Mizoguchi,2 Michiko Narita,2 Hiroshi Nagase,2,3 Tsutomu Suzuki,1 and Leon F. Tseng2 1Department of Toxicology, Hoshi University, School of Pharmacy, Tokyo, 142-8501, Japan, 2Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, and 3Pharmaceutical Research Laboratories, Toray Industries Incorporated, Kamakura 248-8555, Japan The present study was designed to investigate the role of a that were treated with DAMGO. Concomitant intrathecal admin- protein kinase C (PKC) isoform in the uncoupling of the istration of a specific PKC inhibitor Ro-32-0432 with DAMGO ␮-opioid receptor from G-proteins after repeated intrathecal blocked the attenuation of DAMGO-induced G-protein activa- 2 4 injection of a selective ␮-receptor agonist, [D-Ala ,N-MePhe ,Gly- tion that was caused by chronic DAMGO treatment. Western ol 5]enkephalin (DAMGO), in the spinal cord of mice. The activation blotting analysis showed that chronic DAMGO treatment in- of G-proteins by opioids was measured by monitoring the creased the levels of PKC␥, but not PKC␣, PKC␤I, and PKC␤II guanosine-5Ј-o-(3-[ 35S]thio)triphosphate ([ 35S]GTP␥S) binding. isoforms, in spinal cord membranes. Furthermore, mice lacking Mice were injected intrathecally with saline or DAMGO once a day PKC␥ failed to exhibit the desensitization of the DAMGO- for 1–7 d. At 24 hr after every injection the spinal cord membranes stimulated [ 35S]GTP␥S binding after repeated DAMGO injec- were prepared for the assay. The enhanced [ 35S]GTP␥S binding tion. These findings indicate that repeated intrathecal adminis- by ␮-agonists DAMGO, endomorphin-1, or endomorphin-2 was tration of DAMGO may activate the PKC␥ isoform and in turn attenuated clearly in spinal cord membranes obtained from mice cause a desensitization of ␮-receptor-mediated G-protein ac- that were treated intrathecally with DAMGO for 5 and 7 d, but not tivation in the mouse spinal cord. for 1 or 3 d. By contrast, no change in levels of [ 35S]GTP␥S binding induced by the ␦-receptor agonist SNC-80 or ␬-receptor Key words: ␮-opioid receptor; protein kinase C; phosphory- agonist U-50,488H was noted in membranes obtained from mice lation; tolerance; G-protein; spinal cord The opioid agonists modulate a number of physiological pro- PKC is a key regulatory enzyme that modulates both presyn- cesses including pain, reward, stress, and immune responses via aptic and postsynaptic neuronal function, synthesis and release of the stimulation of various opioid receptors (Mansour et al., 1988). neurotransmitters, and the regulation of receptors. PKC has ex- One of the major opioid receptor types, the ␮-opioid receptor, panded into a family of closely related protein, which can be was cloned in 1993 and classified as a G-protein-coupled receptor subdivided and classified on the basis of certain structural and (Chen et al., 1993). Opioids mainly inhibit cyclic AMP formation, biochemical similarities. Several PKC isoforms, especially con- ϩ ϩ close voltage-sensitive Ca 2 channels, and open K channels via ventional PKCs (cPKCs) including ␣, ␤I, ␤II, and ␥ that are 2ϩ the stimulation of Gi/o proteins (Childers, 1991). Over the past Ca -dependent and activated by both phosphatidylserine (Ptd- few years opioids, including ␮-opioids, also have been shown to Ser) and DAG, have been identified in neurons of the spinal cord; activate the phosphoinositide-signaling cascade in a variety of in each case immunocytochemistry has shown that they are con- cells and neural tissues (Chen and Huang, 1991; Mangoura and centrated in the superficial laminae of the dorsal horn (Malmberg Dawson, 1993; Smart et al., 1995; Ueda et al., 1995). et al., 1997; Martin et al., 1999). The receptor-coupled hydrolysis of membranal phosphoinositi- We previously reported that activation of PKC in the spinal des, particularly phosphatidyl inositol 4,5-bisphosphate (PIP2), cord is implicated in the development of spinal antinociceptive yields two intracellular second messengers, diacylglycerol (DAG) tolerance to ␮-opioid receptor agonists in mice (Narita et al., ␮ and inositol triphosphate (IP3). DAG activates protein kinase C 1995). The -opioid receptor contains several potential phos- 2ϩ (PKC), and IP3 mobilizes Ca after binding with cytoplasmic phorylation sites (Chen et al., 1993; Kaufman et al., 1995). It has IP3 receptors (Berridge, 1987; Fisher et al., 1992, 1993). These been hypothesized that activated PKC directly phosphorylates processes appear to be an important part of the signal transduction the opioid receptor and subsequently induces the uncoupling of mechanism for controlling the various cellular events in the CNS. opioid receptors from G-proteins (Pei et al., 1995). However, there is little or no direct evidence to support the contention that ␮ ␮ Received Sept. 12, 2000; revised March 5, 2001; accepted March 13, 2001. repeated stimulation of -opioid receptors by opioid -agonists ␮ This study was supported by National Institutes of Health Grant DA 03811 produces the PKC-dependent uncoupling of -opioid receptors (L.F.T.). from G-proteins. In the present study we therefore investigated Correspondence should be addressed to Dr. Leon F. Tseng, Department of Anesthesiology, MEB-462c, Medical College of Wisconsin, 8701 Watertown Plank whether repeated intrathecal injection of a highly selective 2 4 5 Road, Milwaukee, WI 53226. E-mail: [email protected]. ␮-opioid receptor agonist, [D-Ala ,N-MePhe ,Gly-ol ]enkephalin Copyright © 2001 Society for Neuroscience 0270-6474/01/213715-06$15.00/0 (DAMGO), causes any changes in the increase of ␮-opioid 3716 J. Neurosci., June 1, 2001, 21(11):3715–3720 Narita et al. • Tolerance of ␮-Receptor Function and PKC␥ Ј 35 receptor-stimulated guanosine-5 -o-(3-[ S]thio)triphosphate Table 1. Opioid-induced increase in [35S]GTP␥S binding to spinal cord ([ 35S]GTP␥S) binding and the levels of membrane-located membranes of mice cPKC isoforms in the mouse spinal cord. We also investigated whether repeated intrathecal injections of DAMGO could affect % Stimulation Treatment (% of control) the DAMGO-stimulated [ 35S]GTP␥S binding in mice lacking the PKC␥ isoform. 10 ␮M DAMGO (␮-agonist) 89.2 Ϯ 3.5 10 ␮M DAMGO ϩ 10 ␮M CTOP (␮-antagonist) Ϫ1.6 Ϯ 3.2* MATERIALS AND METHODS 10 ␮M Endomorphin-1 (␮-agonist) 64.8 Ϯ 3.6 Animals. Male CD-1 mice (Charles River Breeding Laboratories, Wil- 10 ␮M Endomorphin-1 ϩ 10 ␮M CTOP 5.7 Ϯ 1.9* ␥ mington, MA) and PKC knock-out mice (The Jackson Laboratory, Bar 10 ␮M Endomorphin-2 (␮-agonist) 68.9 Ϯ 3.4 Harbor, MA), which were maintained on C57BL/6 and 129Sv mixed ␮ ϩ ␮ Ϫ Ϯ genetic backgrounds as described previously (Abeliovich et al., 1993), 10 M Endomorphin-2 10 M CTOP 2.3 0.2* ␮ ␦ Ϯ were used. Animals were housed five per cage in a room maintained at 10 M DPDPE ( -agonist) 18.1 2.4 22 Ϯ 0.5°C with an alternating 12 hr light/dark cycle. 10 ␮M DPDPE ϩ 0.1 ␮M NTI (␦-antagonist) 0.4 Ϯ 1.2* 35 ␥ 2 [ S]GTP S binding assay. The spinal cord was homogenized in ice- 10 ␮M [D-Ala ]deltorphin II (␦-agonist) 38.0 Ϯ 6.0 2ϩ cold Tris-Mg buffer containing (in mM) 50 Tris-HCl, pH 7.4, 5 MgCl2, ␮ 2 ϩ ␮ Ϫ Ϯ 35 ␥ 10 M [D-Ala ]deltorphin II 1 M NTI 0.4 2.7* and 1 EGTA for the [ S]GTP S binding assay. The homogenate was ␮ ␦ Ϯ centrifuged at 48,000 ϫ g at 4°C for 10 min. The pellets were resus- 10 M SNC-80 ( -agonist) 30.4 4.3 35 ␮ ϩ ␮ Ϯ pended in [ S]GTP␥S binding assay buffer containing (in mM)50 10 M SNC-80 1 M NTI 1.5 4.5* Tris-HCl, pH 7.4, 5 MgCl2, 1 EGTA, and 100 NaCl and recentrifuged at 10 ␮M U-50,488H (␬-agonist) 15.3 Ϯ 1.2 ϫ 48,000 g at 4°C for 10 min. The final pellets were resuspended in assay 10 ␮M U-50,488H ϩ 0.1 ␮M nor-BNI (␬-antagonist) 3.5 Ϯ 2.7* 35 ␥ buffer as membranous fractions for the [ S]GTP S binding. The reac- ␮ ␬ Ϯ tion was initiated by the addition of membrane suspension (3–8 ␮gof 10 M U-69,593 ( -agonist) 16.1 2.0 ␮ ϩ ␮ Ϫ Ϯ protein for each assay as determined by the method of Bradford, 1976) 10 M U-69,593 0.1 M nor-BNI 0.6 3.5* into the assay buffer with the opioid receptor agonists, 30 ␮M guanosine- 35 The reaction was initiated by the addition of membrane suspension obtained from 5Ј-diphosphate (GDP), and 50 pM [ S]GTP␥S (1000 Ci/mmol; Amer- the mouse spinal cord into the assay buffer with 10 ␮M opioid, 30 ␮M GDP, and 50 sham, Arlington Heights, IL). The suspensions were incubated at 25°C 35 pM [ S]GTP␥S. Data represent the mean Ϯ SEM for 3–17 samples. The basal for 2 hr, and the reaction was terminated by filtering through Whatman [35S]GTP␥S binding in mice treated with saline for 5 d was 29.2 Ϯ 1.2 fmol/mg GF/B glass filters, which had been soaked previously in a soaking buffer protein. The statistical significance of differences between the groups was assessed Ͻ of 50 mM Tris-HCl, pH 7.4, and 5 mM MgCl2 at 4°C for 2 hr, using a with a one-way ANOVA, followed by Dunnett’s test.
Load more

Recommended publications
  • Evaluation of in Silico Approach for Prediction of Presence of Opioid Peptides in Wheat
    Evaluation of in silico approach for prediction of presence of opioid peptides in wheat This is the Accepted version of the following publication Garg, Swati, Apostolopoulos, Vasso, Nurgali, Kulmira and Mishra, Vijay Kumar (2018) Evaluation of in silico approach for prediction of presence of opioid peptides in wheat. Journal of Functional Foods, 41. 34 - 40. ISSN 1756-4646 The publisher’s official version can be found at https://www.sciencedirect.com/science/article/pii/S1756464617307454 Note that access to this version may require subscription. Downloaded from VU Research Repository https://vuir.vu.edu.au/36577/ 1 1 Evaluation of in silico approach for prediction of presence of opioid peptides in wheat 2 gluten 3 Abstract 4 Opioid like morphine and codeine are used for the management of pain, but are associated 5 with serious side-effects limiting their use. Wheat gluten proteins were assessed for the 6 presence of opioid peptides on the basis of tyrosine and proline within their sequence. Eleven 7 peptides were identified and occurrence of predicted sequences or their structural motifs were 8 analysed using BIOPEP database and ranked using PeptideRanker. Based on higher peptide 9 ranking, three sequences YPG, YYPG and YIPP were selected for determination of opioid 10 activity by cAMP assay against µ and κ opioid receptors. Three peptides inhibited the 11 production of cAMP to varied degree with EC50 values of YPG, YYPG and YIPP were 5.3 12 mM, 1.5 mM and 2.9 mM for µ-opioid receptor, and 1.9 mM, 1.2 mM and 3.2 mM for κ- 13 opioid receptor, respectively.
    [Show full text]
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • Rubsicolins Are Naturally Occurring G-Protein-Biased Delta Opioid Receptor Peptides
    bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title page Title: Rubsicolins are naturally occurring G-protein-biased delta opioid receptor peptides Short title: Rubsicolins are G-protein-biased peptides Authors: Robert J. Cassell1†, Kendall L. Mores1†, Breanna L. Zerfas1, Amr H.Mahmoud1, Markus A. Lill1,2,3, Darci J. Trader1,2,3, Richard M. van Rijn1,2,3 Author affiliation: 1Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, 2Purdue Institute for Drug Discovery, 3Purdue Institute for Integrative Neuroscience, West Lafayette, IN 47907 †Robert J Cassell and Kendall Mores contributed equally to this work Corresponding author: ‡Richard M. van Rijn, Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907 (Phone: 765-494- 6461; Email: [email protected]) Key words: delta opioid receptor; beta-arrestin; natural products; biased signaling; rubisco; G protein-coupled receptor Abstract: 187 Figures: 2 Tables: 2 References: 27 1 bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The impact that β-arrestin proteins have on G-protein-coupled receptor trafficking, signaling and physiological behavior has gained much appreciation over the past decade. A number of studies have attributed the side effects associated with the use of naturally occurring and synthetic opioids, such as respiratory depression and constipation, to excessive recruitment of β-arrestin.
    [Show full text]
  • Intravta Deltorphin, but Not DPDPE, Induces Place Preference in Ethanoldrinking Rats
    ALCOHOLISM:CLINICAL AND EXPERIMENTAL RESEARCH Vol. 38, No. 1 January 2014 Intra-VTA Deltorphin, But Not DPDPE, Induces Place Preference in Ethanol-Drinking Rats: Distinct DOR-1 and DOR-2 Mechanisms Control Ethanol Consumption and Reward Jennifer M. Mitchell, Elyssa B. Margolis, Allison R. Coker, Daicia C. Allen, and Howard L. Fields Background: While there is a growing body of evidence that the delta opioid receptor (DOR) modu- lates ethanol (EtOH) consumption, development of DOR-based medications is limited in part because there are 2 pharmacologically distinct DOR subtypes (DOR-1 and DOR-2) that can have opposing actions on behavior. Methods: We studied the behavioral influence of the DOR-1-selective agonist [D-Pen2,D-Pen5]- Enkephalin (DPDPE) and the DOR-2-selective agonist deltorphin microinjected into the ventral tegmental area (VTA) on EtOH consumption and conditioned place preference (CPP) and the physio- logical effects of these 2 DOR agonists on GABAergic synaptic transmission in VTA-containing brain slices from Lewis rats. Results: Neither deltorphin nor DPDPE induced a significant place preference in EtOH-na€ıve Lewis rats. However, deltorphin (but not DPDPE) induced a significant CPP in EtOH-drinking rats. In con- trast to the previous finding that intra-VTA DOR-1 activity inhibits EtOH consumption and that this inhibition correlates with a DPDPE-induced inhibition of GABA release, here we found no effect of DOR-2 activity on EtOH consumption nor was there a correlation between level of drinking and deltorphin-induced change in GABAergic synaptic transmission. Conclusions: These data indicate that the therapeutic potential of DOR agonists for alcohol abuse is through a selective action at the DOR-1 form of the receptor.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Receptor Types
    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 3180-3184, April 1990 Pharmacology Chimeric opioid peptides: Tools for identifying opioid receptor types (dynorphin/dermorphin/deltorphin/monoclonal antibody/panning) Guo-xi XIE*t, ATSUSHI MIYAJIMA*, TAKASHI YOKOTA*, KEN-ICHI ARAI*, AND AVRAM GOLDSTEINt *Department of Molecular Biology, DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA 94304; and tDepartment of Pharmacology, Stanford University, Stanford, CA 94305 Contributed by Avram Goldstein, January 23, 1990 ABSTRACT We synthesized several chimeric peptides in was assumed that the C-terminal amide group ofdermorphin, which the N-terminal nine residues of dynorphin-32, a peptide deltorphins, and DSLET and the alcohol group of DAGO selective for the K opioid receptor, were replaced by opioid could be removed without affecting opioid binding. By anal- peptides selective for other opioid receptor types. Each chi- ogy to dyn-32, which binds selectively to K opioid sites, meric peptide retained the high affminty and type selectivity DAGO-DYN and dermorphin-DYN should bind selectively characteristic of its N-terminal sequence. The common C- to p.; deltorphins-DYN and DSLET-DYN should bind selec- terminal two-thirds of the chimeric peptides served as an tively to 8. mAbs 17.M and 39 should act as nonblocking epitope recognized by the same monoclonal antibody. When antibodies to all these peptides. bound to receptors on a cell surface or membrane preparation, In the present study, we have demonstrated that the these peptides could still bind specifically to the monoclonal chimeric peptides do maintain the high affinities and type antibody. These chimeric peptides should be useful for isolating selectivities of their N-terminal sequences.
    [Show full text]
  • Efficacy and Safety of Gluten-Free and Casein-Free Diets Proposed in Children Presenting with Pervasive Developmental Disorders (Autism and Related Syndromes)
    FRENCH FOOD SAFETY AGENCY Efficacy and safety of gluten-free and casein-free diets proposed in children presenting with pervasive developmental disorders (autism and related syndromes) April 2009 1 Chairmanship of the working group Professor Jean-Louis Bresson Scientific coordination Ms. Raphaëlle Ancellin and Ms. Sabine Houdart, under the direction of Professor Irène Margaritis 2 TABLE OF CONTENTS Table of contents ................................................................................................................... 3 Table of illustrations .............................................................................................................. 5 Composition of the working group ......................................................................................... 6 List of abbreviations .............................................................................................................. 7 1 Introduction .................................................................................................................... 8 1.1 Context of request ................................................................................................... 8 1.2 Autism: definition, origin, practical implications ........................................................ 8 1.2.1 Definition of autism and related disorders ......................................................... 8 1.2.2 Origins of autism .............................................................................................. 8 1.1.2.1 Neurobiological
    [Show full text]
  • (D-Ala*)Deltorphin II: D,-Dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens
    The Journal of Neuroscience, June 1991, 17(6): 1565-l 576 (D-Ala*)Deltorphin II: D,-dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens R. Longoni,’ L. Spina,’ A. Mulas,’ E. Carboni,’ L. Garau,’ P. Melchiorri,2 and G. Di Chiaral ‘Institute of Experimental Pharmacology and Toxicology, University of Cagliari, 09100 Cagliari, Italy and 21nstitute of Medical Pharmacology, University of Rome “La Sapienza,” 00185 Rome, Italy In order to investigate the relative role of central 6- and has been implicated in the stimulant actions of systemic opiates. F-opioid receptors in behavior, the effects of (D- Morphine-like opiates stimulate DA release preferentially in the Ala*)cleltorphin II, a natural Gopioid peptide, and PL017, nucleus accumbens (Di Chiara and Imperato, 1988a) and elicit a beta-casomorphin derivative specific for mu receptors, hypermotility sensitive to blockade by the DA D, receptor an- were compared after local intracerebral and intraventricular tagonist SCH 23390 (Longoni et al., 1987a). Intra-accumbens administration. lntracerebral infusion of the two peptides was infusion of opioid peptides elicits motor stimulation, but this done bilaterally in the limbic nucleus accumbens and in the action seems independent from DA, being resistant to classic ventral and dorsal caudate putamen of freely moving rats DA-receptor antagonists (neuroleptics; Pert and Sivit, 1977; Ka- through chronic intracerebral cannulas. After intra-accum- livas et al., 1983). Moreover, the syndrome elicited by intra- bens infusion, the two peptides elicited marked but opposite accumbens opiates is biphasic, as motor stimulation is typically behavioral effects: while (o-Ala2)deltorphin II evoked dose- preceded by motor inhibition and catalepsy (Costa11et al., 1978).
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Review of the Potential Health Impact of Β-Casomorphins and Related Peptides 1
    EFSA Scientific Report (2009) 231, 1-107 SCIENTIFIC COOPERATION AND ASSISTANCE SCIENTIFIC REPORT OF EFSA Review of the potential health impact of β-casomorphins 1 and related peptides Report of the DATEX Working Group on β-casomorphins (Question N° EFSA-Q-2008-379) Issued on 29 January 2009 WORKING GROUP MEMBERS Ivano De Noni, Richard J. FitzGerald, Hannu J. T. Korhonen, Yves Le Roux, Chris T. Livesey, Inga Thorsdottir, Daniel Tomé, Renger Witkamp. 1 For citation purposes: Scientific Report of EFSA prepared by a DATEX Working Group on the potential health impact of β-casomorphins and related peptides. EFSA Scientific Report (2009) 231, 1-107 © European Food Safety Authority, 2009 Review of the potential health impact of β-casomorphins and related peptides SUMMARY Proteins are a very diverse family of large organic compounds involved in many important biological processes. Following their enzymatic hydrolysis during food processing or digestion, proteins may release fragments from their primary amino acid sequence. These fragments are called peptides, and many of them are known to be physiologically active. The possible beneficial effects of bioactive peptides have attracted increasing interest in recent years. On the other hand, there are also reports suggesting that some food-derived peptides might adversely affect human health. Among these, β-casomorphin-7 (BCM7), a peptide sequence present in the milk protein β-casein, has been suggested to contribute to an increased risk for certain non-communicable diseases, such as autism, cardiovascular diseases and type I diabetes. Some literature reports have proposed possible mechanistic explanations for such associations Recognising the alleged negative effect of BCM7 on human health, EFSA deemed it necessary to perform a comprehensive review of the published scientific literature in order to assess the relationship of this peptide and related peptides with non-communicable diseases.
    [Show full text]
  • Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity
    pharmaceutics Review Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity Junzhi Yang 1, Bianca G. Reilly 2, Thomas P. Davis 1,2 and Patrick T. Ronaldson 1,2,* 1 Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, 1295 N. Martin St., P.O. Box 210207, Tucson, AZ 85721, USA; [email protected] (J.Y.); [email protected] (T.P.D.) 2 Department of Pharmacology, College of Medicine, University of Arizona, 1501 N. Campbell Ave, P.O. Box 245050, Tucson, AZ 85724-5050, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-520-626-2173 Received: 19 September 2018; Accepted: 16 October 2018; Published: 18 October 2018 Abstract: Opioids are highly effective analgesics that have a serious potential for adverse drug reactions and for development of addiction and tolerance. Since the use of opioids has escalated in recent years, it is increasingly important to understand biological mechanisms that can increase the probability of opioid-associated adverse events occurring in patient populations. This is emphasized by the current opioid epidemic in the United States where opioid analgesics are frequently abused and misused. It has been established that the effectiveness of opioids is maximized when these drugs readily access opioid receptors in the central nervous system (CNS). Indeed, opioid delivery to the brain is significantly influenced by the blood-brain barrier (BBB). In particular, ATP-binding cassette (ABC) transporters that are endogenously expressed at the BBB are critical determinants of CNS opioid penetration. In this review, we will discuss current knowledge on the transport of opioid analgesic drugs by ABC transporters at the BBB.
    [Show full text]
  • Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAINNONCANCER CHRONIC Evidence Review
    CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN GUIDELINE FOR THE Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAIN Evidence Review The American Pain Society in Conjunction with The American Academy of Pain Medicine EVIDENCE REVIEW APS-AAPM Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain TABLE OF CONTENTS Page Introduction 1 Purpose of evidence review ...................................................................... 1 Background 1 Previous guidelines ................................................................................... 2 Scope of evidence review 3 Key questions............................................................................................ 3 Populations................................................................................................ 7 Interventions.............................................................................................. 8 Outcomes.................................................................................................. 8 Conflict of interest............................................................................................. 10 Methods 10 Literature search and strategy................................................................... 10 Inclusion and exclusion criteria.................................................................. 11 Data extraction and synthesis ..................................................................
    [Show full text]